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disease) have also proved useful in some limited cases. The actual situation of reemergence of sleeping sickness in sub-Saharan Africa, with prevalence of an estimated 500,000 infected individuals, 3 and the drawbacks of the current HAT chemotherapy (e.g. toxicity, increasing resistance, parenteral mode of administration, price) make the search for new trypanocidal drugs urgently needed. 4 Many diamidine, diguanidine and polyamine compounds have been investigated for their antitrypanosomal activity as far as 65 years ago, [5] [6] [7] [8] [9] [10] [11] giving rise, for instance, to the aromatic diamidine drug pentamidine 12 which is still used nowadays for the treatment of early stage T.b. gambiense infections. However, this drug is unable to cross the blood-brain barrier in sufficient quantity to treat late-stage cases of HAT. 13 Other aromatic diamidines such as propamidine or berenil are used as antiprotozoal chemotherapy in cattle and the trypanocidal activity of dicationic derivatives related to pentamidine have been reported as well (Figure 1) . 9, 14, 15 The polyamine metabolic pathway of trypanosomatid parasites has attracted much attention as drug target for the last 15 years. 16 This research led to the synthesis and evaluation of many polyamine analogues as chemotherapeutic agents against parasitic infections, [17] [18] [19] [20] being the trypanothione reductase a particularly targeted enzyme (Figure 1 ). [21] [22] [23] There is a clear lack of research investment in the field of tropical diseases in comparison to the number of affected population. 24, 25 Thus, a reasonable approach for the discovery of new anti-trypanosomal lead compounds at a lesser cost is the screening for anti-parasitic activity of already available molecules. Hence, a rapid look at the structure of the polyamine, diguanidine and diamidine compounds reported as antiprotozoal agents in the literature put into evidence the potential as possible trypanocides of a series of bisguanidine and bis(2-aminoimidazoline) compounds previously synthesized in our laboratory for other purposes. [26] [27] [28] Moreover, some of the alkanediguanidine [1, 8-octanediguanidine (1b) , 29 1,12-dodecanediguanidine (1d), 6, 30, 31 bis(guanidinopropyl)amine (6a trypanosomal agent in vivo. 15 Hence, in the search for new HAT chemotherapy, we decided to carry out an in vitro screening against the parasite T. brucei rhodesiense of a total of 62 compounds (Tables 1-5 ) taken from our in-house library and structurally related to the trypanocidal agents synthalin (1,10-decanediguanidine) and 4,4'-diguanidinodiphenylmethane (31b), and the polyamine N 1 -(3-amino-propyl)-propane-1,3-diamine respectively. We also describe here the original synthesis of 21 molecules which had not been previously reported.
Results

Chemistry
Synthesis of the aliphatic compounds 1a-d, 2a-d, 3b-d, 4a-b, 5a, 5b, 5d, 6a-b, 7, 8, 9, 11-13, 21-24 (Tables 1, 2 , 3 and 4) as well as the diphenyl derivatives 27a-33a, 27b-33b and 34 (Table 5 , entry 1-15) has been previously reported by us. 26, 27, 28 Synthesis of the 3-aza-1,6-hexanediamine derivatives (Scheme 1). Guanylation of 3-aza-1,6-hexanediamine with an excess of DCC in CH 3 CN afforded a mixture of the di-substituted dicyclohexylguanidine derivative 5c and the tri-substituted compound 17. These products were separated by preparative reverse phase HPLC. In this reaction, two cyclisation products could potentially form: (1H-imidazol-2-yl)-aryl-amine ("endocyclic" amino group) and 1-aryl-1H-imidazol-2-ylamine ("exocyclic" amino group).
1 H NMR spectrum of 35 showed a unique broad singlet for 4-H and 5-H imidazol protons at 6.76 ppm whereas decoupled 13 C NMR spectrum showed a unique signal for both 4-and 5-imidazole carbons indicating the magnetic equivalence of these atoms. These data demonstrated that the expected product 35 with the endocyclic amino group was obtained (e.g. if the isomer with exocyclic amino group were obtained, a typical AB system would be observed for the 4-and 5-H imidazol protons). Compound 37 has been previously described 37 as a B 2 bradykinin receptor antagonist. The reported procedure was quite lengthy so we designed a three steps synthesis starting from 4,4'-dimethylbenzophenone. Radicalar bromination of 4,4'-dimethylbenzophenone with NBS/t-BuOOH/CCl 4 allowed the formation of the dibromo-derivative compound 36 which was isolated by crystallisation from the reaction mixture (22 % yield). The low yield obtained could be explained by the formation of a mixture of mono-and poly-halogenated derivatives (e.g. three spots were observed by TLC of the crude reaction mixture). 38 The bis-phosphonium compound 37
was obtained by nucleophilic substitution of the bromine atoms of 36 with an excess of tri-n-pentylphosphine in refluxing toluene. Tri-n-pentylphosphine was prepared by a modification of the procedure described by Davies et al.. 39 The reaction of an excess of bromopentane Grignard's reagent with phosphorous trichloride working at -78 ºC 40 afforded the tri-n-pentylphosphine which was purified by fractional distillation.
Synthetic approach for the preparation of the piperazine-based bisguanidine and bis(2-aminoimidazoline) compounds is depicted in scheme 3. Aromatic nucleophilic substitution of 1-fluoro-4-nitrobenzene with the commercially available 1-(4-nitrophenyl)-piperazine in DMSO at 100 ºC afforded 38. ranging from 13 (1d) to more than 5000 (1c).
Alkane and aza-alkane derivatives (Tables 1 and 2 ). The most potent compound within the alkane (Table 1) and aza-alkane (Table 2) derivative series was 1,9-nonanediguanidine (1c) with IC 50 = 49 nM and a remarkable selectivity for the parasite (SI > 5294). In these series, the guanidinium cation gave in general more active compounds (about 2 to 4-fold) than the 2-aminoimidazolinium counterpart (compare
This was also true for the aza-alkane series ( Table 2 , 5a/5b and 6a/6b).
Increasing the chain length of the methylene spacer (n = 6, 8, 9, 12) between either guanidinium or 2-aminoimidazolinium cations tended to increase the activity with the following order: n = 6 < n = 8 (ca 30-fold) < n = 9 ~ n = 12 (Table 1) . Regarding the selectivity, the nine-methylene spacer (1c and 2c) gave the best SI (5294 and 71) in both series. Noteworthy was the greater activity displayed by the dicationic derivatives 1b-d
and 2b-d with respect to their monocationic counterparts (Table 1) . This behaviour was also observed for the aza-alkane compound 6b which was 3.5-fold more active than 7
( Table 2) . Tables 1 around here   44 Introduction of an unsubstituted nitrogen atom in the methylene chain (e.g. in the aza-alkane series, Table 2 ) tended to reduce the activity compared to alkyl spacer. This is exemplified by the activity of compounds 1a and 2a (8 and 19.3 µM respectively) and their aza-analogues 5a and 5b (21.4 and 69.1 µM respectively). Another interesting result was that of the dicyclohexylguanidine 5c (IC 50 = 2.4 µM) which was 9-fold more active than the guanidine analogue 5a (21.4 µM). This result might reflect better pharmacokinetic properties of the more lipophilic derivative 5c (i.e. to cross biological membranes). Tables 2 around here The dicyclohexylguanidine compound 17 (IC 50 = 0.98 µM) displayed the best activity and selectivity (SI > 82) of all the 3-aza-1,6-hexanediamine derivatives (Table   3) . Again, it appeared that lipophilicity was an important factor for good activity. In this series, substitution of the secondary amino group with a phenethyl, 3(2-ethyl)indole or methyl group afforded molecules slightly more active than the parent compound (compare the activities of 10/5a, 11/5b and 16/5b). 45 In addition, the amines protected with a carbobenzyloxy group (Cbz) were more active than their free amino counterparts (Table   4) , which showed the same range of activity as the parent compound 14 (IC 50 = 3.1 µM, Table 3 ) but a lower selectivity (SI = 27 and 18.6 respectively, compared to 41 for 14).
This behaviour was also observed with the cyclic analogue 23 (71.2 µM) which displayed the same activity as the aliphatic parent 5b (69.1 µM). Table 4 around here Diphenyl derivatives (Table 5 ). In this series of bisguanidine and bis(2-aminoimidazoline) diphenyl analogues (Entry 1-17), best activities were observed for the compounds bearing a guanidinium group (from 3-to 10-fold with respect to the imidazoline analogues). However, the 2-aminoimidazoline derivatives displayed, in general, better selectivity than the guanidine counterparts (compare the activity and selectivity of 31b/27b, 32b/28b, 34/29b and 32a/28a). In addition, replacement of the guanidine or 2-aminoimidazoline with a 2-aminoimidazole nucleus (compound 35, entry 18) produced a loss of activity of 20-and 63-fold compared to 28b and 32b
respectively. Interestingly, the very lipophilic bis-phosphonium benzophenone derivative 37 showed a trypanocidal activity (IC 50 = 0.414 µM) similar to that of the bisguanidinium diphenylketone 34 (0.206 mM) and a better selectivity (SI = 28.5 versus
13.1).
Notable is the effect of the N-substitution of the imidazoline and guanidine moieties (i.e. Boc, CH 2 CH(OEt) 2 ). Boc protection afforded less active compounds compared to unprotected counterparts (compare 27a/27b, 29a/29b, 31a/31b, 32a/32b, 33a/ 33b and 40a/40b) with the exception of 28 and 30 in which the Boc substituents produced a 1.4
and 12-fold increase in activity respectively (IC 50 = 0.048 and 2.6 µM respectively) compared to the free imidazolinium cation (IC 50 = 0.069 and 32.4 µM respectively).
Moreover, the Boc substituents seemed to give somewhat less selective compounds (SI = 202 and 3072 for 28a and 28b respectively; SI = 7.9 and 29.5 for 32a and 32b). On the contrary, the 1,1-diethoxyethane substituent produced a great increase in selectivity, superior to 26-and 32-fold for 31c and 32c respectively, with only a slight loss in activity (2-and 10-fold respectively) compared to the unsubstituted parent compounds 31b and 32b. Regarding the bridge linking both phenyl rings, the same behaviour was observed for the guanidinium and 2-aminoimidazolinium series, i.e. NH >> CH 2 > CO > SO 2 in order of decreasing activity (compare 27b-30b and 31b-33b, 34). When a piperazine moiety was used as bridge between both phenyl rings ( Table 5 , entry 21-25), the 2-aminoimidazolinium compound 41b showed the best activity (0.118 µM) and also a 5 times higher selectivity (SI = 881) with respect to the guanidinium analogue (SI = 172).
Discussion
Some of the compounds described in this manuscript were available in our in-house library. Since few of these molecules had been previously reported in the literature for their anti-trypanosomal activity (e.g. 1d, 5 31b, 8 33b 10 ), we anticipated that our compounds would display trypanocidal action. Indeed, simple aliphatic diguanidines were potent and selective trypanocides, with 3c (SI > 5294) being more selective than the control melarsoprol (SI = 3456). The potency of 3c is to be compared with that of synthalin (1,10-decanediguanidine) 7 or 1,11-undecanediamidine, a trypanocidal drug which proved able to cure mice and rabbits infected with a strain of T.b. rhodesiense.
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The 1,9-nonanediguanidine 3c could be considered as the bio-isostere of 1,11-undecanediamidine with the supplementary amino groups of the guanidine moieties playing the role of the two supplementary methylene units, thus keeping approximately the same chain length in both molecules.
In those series, the guanidine moiety afforded in general better trypanocidal drugs than the 2-aminoimidazoline one. Moreover, the presence of two cations was required for potent activity, which is in agreement with the results previously obtained by King et al. 6 This assumption could probably be extended to the diphenyl series, according to the previous findings reported for aromatic diamidines and diguanidines, 6,9,10 although this hypothesis was not tested here because mono-cationic aromatic compounds were not available in our library. The most interesting results probably came from the diphenyl series with a NH bridge. The bis(2-aminoimidazoline) derivative 28b was extremely potent (IC 50 = 69 nM) and also highly selective for the parasite (SI = 3072). The Boc-protected counterpart 28a had the same range of activity but a lower selectivity index (SI = 202).
This result in particular might be relevant because of the higher lipophilicity of the Bocprotected compound 28a. Late-stage cases of HAT involve CNS infection and hence, require drugs able to cross the blood-brain barrier. However, the Boc-protecting group is probably stable in the conditions of the in vitro assay but potentially could be metabolised in vivo to afford the unprotected derivative 28b.
Changing the 2-aminoimidazolinium cations for guanidinium ones led to the most active compound of this screening: 32b ( where electron-rich phenyl groups (e.g. phenoxy) afforded better trypanocides than electron-poor phenyl rings (e.g. acetylated aniline or pyridine). 15 If we compare the different cationic species studied (i.e. guanidinium, 2-aminoimidazolinium, phosphonium), the good activity and selectivity displayed by the bis-phosphonium derivative 37 (IC 50 = 0.414 µM, SI = 28.5) is of particular interest.
These results suggest that lipophilic bis-phosphonium diphenyl derivatives might be a good alternative (with potentially better pharmacokinetic properties) to the guanidine or 2-aminoimidazoline derivatives. With respect to the guanidine cation, N-substitution with a diethoxyethane moiety afforded highly selective anti-trypanosomal agents (SI > 754 and 767 for 31c and 32c respectively).
Anti-trypanocidal efficacy of a drug depends on its effective uptake by the parasite.
It is known that diamidines such as pentamidine, which have very slow rate of diffusion across biological membranes, can be transported into the cell by a P2-amino-purine transporter that specifically recognises the main H 2 N-C(R 1 )=NR 2 motif. 46, 47 The guanidine molecules reported here also present this recognition motif. In the case of the diphenyl derivatives, most of the Boc-protected molecules (i.e. the most lipophilic)
showed a weaker activity than the charged, unprotected, guanidinium analogues. This might account for a more efficient transport of the unprotected derivatives through the P2 transporter, although affinity assays for this transporter remain to be done.
It is still too early to propose a mode of action of the compounds presented here and further studies are needed. However, a number of dicationic molecules belonging to the diamidine family (e.g. pentamidine) are known to bind to the minor-groove of DNA and their antiprotozoal activity is thought to be the result of that interaction (e.g. inhibition of DNA dependant enzymes or inhibition of transcription). [48] [49] [50] In a recent article, Donkor et al. studied the trypanocidal activity of a series of conformationally restricted congeners of pentamidine. 15 Although a direct correlation between the DNA binding affinity and the trypanocidal activity was not observed, the authors concluded that compounds with strong DNA affinity generally showed good trypanocidal activity in that series. In particular, N,N'-bis(4-amidinophenyl)piperazine (Figure 1) and N,N'-bis(4-imidazolinophenyl)piperazine were the most potent trypanocides and also the strongest DNA binders in this series. According to the results of Donkor et al., we might expect good DNA binding affinity for compounds 40b and 41b, which are the guanidine and 2-aminoimidazoline analogues of these congeners respectively (vide infra). However, this hypothesis will need experimental confirmation.
Several compounds presented in this paper were first and foremost studied for different activities on the CNS (i.e. α 1 -adrenergic antagonism, I 2 -imidazoline binding site affinity or analgesic properties). The knowledge of these interactions (i.e. possible side effects) is of importance because useful anti-trypanocidal agents are expected to penetrate the CNS to cure late-stage cases of HAT. The diphenyl compounds (Table 5, entries 5-8 and 12-15) present α 1 -adrenergic antagonist activity in various tissues. 26, 51 In particular, the blood pressure and heart rate responses of two compounds (29b and 31b)
had been tested on rats in vivo, suggesting a smaller magnitude of cardiovascular effects than the α 1 -adrenergic antagonist Doxazosin at the same dose. 52 On the other hand, the alkane derivatives (Table 1 , 1a-d and 2a-d) showed a moderate to good affinity for the I 2 -imidazoline binding sites and α 2 -adrenoceptors in human brain membranes. 27 Finally, several aza-alkane derivatives (Tables 2 and 3 : 4a-b, 5a-b, 6a-b, 7, 10, 11, 23) were tested for analgesic activity in mice. 28 These data are relevant and should be taken into consideration when choosing possible lead compounds for in vivo assays.
Conclusion
We have reported here the screening for trypanocidal activity against T.b. 
Experimental Section
Chemistry. All reaction solvents were purchased anhydrous and used as received.
Other solvents used were reagent grade. Reactions were monitored by TLC using precoated silica gel 60 F254 plates. Chromatography was performed either with silica gel 60 PF 254 (particle size 40-63 µm) or with a medium pressure chromatography system using KP-Sil™ 40S or 40M cartridges (particle size 32-63µm, 60Å HPLC (column II): R t = 9.37 min (100 %).
3-Azahexane-1,3,7-(N,N'-dicyclohexyl)triguanidine (17 
{3-[(2-Benzyloxycarbonylamino-ethyl)-(2-chloro-ethyl)-amino]-propyl}-
carbamic acid benzyl ester (19) . Chloroacetaldehyde (50 % in water, 1.5 mL, 11.6 mmol) was added to a solution of 5d (1.11 g, 2.9 mmol) in CH 3 CN (20 mL). After a few minutes, AcOH (0.5 mL, 8.5 mmol)) was added, followed 5 min later by NaBH(OAc) 3 (1.24g, 5.8 mmol). The reaction mixture was stirred for 4 h at room temperature adjusting the pH to 5-6 with AcOH during the course of the reaction. The reaction was quenched by careful addition of 5 % NaHCO 3 and diluted with CH 2 Cl 2 .
The organic phase was separated and the aqueous phase was extracted 3 times with 3-(3-Benzyloxycarbonylamino-propyl)-imidazolidine-1-carboxylic acid benzyl ester (25) . To a solution of amine 5d (1.06 g, 2.7 mmol) and formaldehyde (37 % in H 2 O, 1.5 mL, 13.5 mmol) in CH 3 CN was added NaBH 3 CN (226 mg, 3.6 mmol).
After 10 min, few drops of AcOH were added to the cloudy solution to adjust the pH to 6-7. The reaction was stirred 17 h at room temperature and the solvent was removed by reduce pressure. The crude residue was treated with water and 1M NaOH was added to adjust the pH to 10-11. The aqueous phase was extracted 3 times with CH 2 Cl 2 and the organic extracts were dried (Na 2 SO 4 ) and concentrated by reduce pressure. The crude oil was chromatographed (40M cartridge) with CH 2 Cl 2 /MeOH (98:2). The sixmembered heterocycle 26 was eluted first followed by 25. 
Biological tests
In Vitro antitrypanosomal activity against Trypanosoma brucei rhodesiense.
Minimum Essential Medium (50 µl) supplemented with 25 mM HEPES, 1g/l additional glucose, 1% MEM non-essential amino acids (100x), 0.2 mM 2-mercaptoethanol, 2mM
Na-pyruvate, 0.1mM hypoxanthine and 15% heat inactivated horse serum was added to each well of a 96-well microtiter plate. 3-fold serial drug dilutions were prepared in duplicate in the columns covering a range from 90 µg/ml to 0.123 µg/ml. Table 3 . Structure, in vitro trypanocidal activity and cytotoxicity of 3-aza-1,6-hexanediamine derivatives 8-20. 
